ArticleClinical, cosmetic and investigational dermatology2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.
Article in Clinical, cosmetic and investigational dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.The Journal of dermatology · 2026Article
- Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies.Dermatology and therapy · 2026Article
- Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).Pharmacy (Basel, Switzerland) · 2026Article
- Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.Dermatology and therapy · 2026Review
- A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026Review
- IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026Review
- Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program.Dermatology and therapy · 2025Article
- Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?Journal of clinical medicine · 2025Article
- Biologics and small molecules for psoriasis: current and future progress.Drugs in context · 2025Review
- Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.Drugs in context · 2025Article
- Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.Psoriasis (Auckland, N.Z.) · 2025Article
- Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT).Acta dermato-venereologica · 2024Observational
- The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials.Clinical, cosmetic and investigational dermatology · 2024Review
- Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.Drugs in context · 2024Article
- Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.Clinical, cosmetic and investigational dermatology · 2024Article
- Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.Pediatric health, medicine and therapeutics · 2023Review
- Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?Clinical, cosmetic and investigational dermatology · 2023Review
- Biologics for the Management of Erythrodermic Psoriasis: An Updated Review.Clinical, cosmetic and investigational dermatology · 2023Review
- Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada.Journal of cutaneous medicine and surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 and reSURFACE-2), comparing tildrakizumab superiority to placebo and etanercept. Due to its recent availability in clinical-practice, real-life data are still limited. Objective: To assess the efficacy and safety of tildrakizumab in a real-world-practice in patients suffering from moderate-to-severe psoriasis. Methods: A 52-week observational retrospective study enrolled patients suffering from moderate-to-severe plaque-psoriasis, starting tildrakizumab treatment. Results: A total of 42 patients were included in the study. Mean PASI showed a significant reduction at each follow-up (p<0.001), reducing from 13.5±5.9 at baseline, 2.8±3.8 at week-28, resulting stable up to week-52. High rates of patients reached both PASI90 and PASI100 responses at both week 16 (PASI90: 52.4%, PASI100: 33.3%) and week 28 (PASI90: 76.1%, PASI100: 61.9%), maintaining these up to week 52 (PASI90: 73.8%, PASI100: 59.5%). The impact of treatment on patient's quality of life has been evaluated with DLQI, which showed a significant reduction during follow-ups. Conclusion: Our data confirm tildrakizumab as an effective and generally safe treatment for the management of moderate-to-severe psoriasis, with high rates of both PASI90 and PASI100 responses, and very few reported adverse events, up to 52 weeks of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.